Gout Pharmacology: Allopurinol, Colchicine, Urate Targets and Flare Management

Evidence-informed pharmacology review, updated 10 November 2026. For education; use current local guidance and individual clinical assessment.

Overview

Gout is an inflammatory arthritis caused by monosodium urate crystal deposition in joints and tissues. Hyperuricemia arises from urate overproduction or, more commonly, impaired excretion; hyperuricosuria is not required. Treat acute inflammation promptly and use urate-lowering therapy (ULT) when indicated to prevent future attacks and dissolve deposits [1,2].

Classification and mechanisms

  • Xanthine oxidase inhibitors: allopurinol, converted to oxypurinol, and febuxostat reduce uric acid synthesis.
  • Uricosurics: probenecid promotes renal urate excretion; effectiveness and stone risk depend on kidney function and patient factors.
  • Uricase: IV pegloticase converts urate to allantoin and is reserved for severe refractory gout; rasburicase is for tumor lysis-related hyperuricemia, not standard chronic gout treatment.
  • Acute anti-inflammatory therapy: colchicine inhibits microtubule polymerization and neutrophil-mediated inflammation; NSAIDs and glucocorticoids suppress inflammatory pathways. Selected IL-1 inhibitors are options in specialist-refractory situations [1,2].

Treat-to-target strategy

The 2020 ACR guideline strongly recommends allopurinol as preferred first-line ULT, including in chronic kidney disease, with a low initial dose (often ≤100 mg/day and lower in CKD), gradual titration and serial serum urate testing to achieve less than 6 mg/dL. ULT is especially indicated with tophi, gout-related radiographic damage or frequent flares. Continue ULT during flares; starting ULT during a flare can be reasonable with adequate anti-inflammatory treatment. Provide anti-inflammatory prophylaxis for at least 3–6 months when initiating ULT [2].

Gout flare treatment

Start an appropriate NSAID, low-dose colchicine or oral/intra-articular glucocorticoid early, considering kidney function, interactions, cardiac risk, infection and the number of involved joints. Do not give antibiotics for a crystal flare unless infection is suspected or proven. Septic arthritis can coexist with gout and must be excluded in high-risk presentations [1,2].

Safety and major interactions

Allopurinol can cause severe hypersensitivity; ACR recommends HLA-B*58:01 testing before initiation in patients of Southeast Asian descent (for example Han Chinese, Korean and Thai) and African American patients. Febuxostat has cardiovascular safety concerns requiring individualized selection. Colchicine is a CYP3A4 and P-glycoprotein substrate; clarithromycin, strong inhibitors and renal/hepatic dysfunction can precipitate fatal toxicity. Allopurinol or febuxostat with azathioprine/mercaptopurine can cause profound marrow suppression without specialist dose modification or avoidance. Pegloticase requires G6PD screening because of hemolysis risk [1,2].

Outdated treatments and practical advice

Lesinurad was withdrawn from several markets and should not be presented as a routinely available gout medicine. Lifestyle measures can complement, but not replace, indicated ULT; assess alcohol intake, weight, diuretics and other contributors without stigmatizing patients [2].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72:744–760. doi:10.1002/acr.24180. Available from: https://doi.org/10.1002/acr.24180
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *